Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease.

ABSTRACT:

Background

The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease.

Methods

The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA).

Results

The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs

SUBMITTER: Gisondi P 

PROVIDER: S-EPMC9142895 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature